Want to join the conversation?
Despite the court ruling, $SHPG believes the proposed Zydus product infringes its patent. Company will continue to defend its intellectual property rights. $SHPG has 30 days to file an appeal to the Court of Appeals. Zydus does not have a tentative or final approval of their ANDA, which is necessary for commercial introduction of a generic product.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.